Genetic Spectrum of Non‐ PTPN11 Variants in Noonan Syndrome and Related RASopathies : Findings From a Russian Cohort
Clinical Genetics · 2026
DOI: 10.1111/cge.70211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Anna Orlova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia. Hauptthemen laut MEDLINE: Noonan Syndrome, Protein Tyrosine Phosphatase, Non-Receptor Type 11, ras Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Noonan syndrome (NS) and related RASopathies form a clinically and genetically heterogeneous group of disorders caused by germline dysregulation of the RAS/MAPK pathway. Pathogenic variants in PTPN11 account for roughly half of classical NS, but the contribution of non‐PTPN11 genes in patients referred with NS or Noonan‐like phenotypes remains incompletely defined in several populations, including Russia. We characterized the spectrum of non‐PTPN11 variants in a large Russian cohort referred for suspected NS or Noonan‐like phenotypes and examined gene‐specific clinical patterns. We analyzed 456 unrelated patients with clinically diagnosed NS or Noonan‐related syndromes using a targeted panel of 23 RAS/MAPK pathway genes. PTPN11 variants (23% of cases) were reported previously; here we focused on the remaining patients. Pathogenic or likely pathogenic variants were identified in 19% of cases (85/456), with NF1, SOS1, SHOC2, and BRAF being the most frequently mutated genes, together accounting for 50% of the non‐PTPN11 diagnoses. Novel variants were observed in 12.1% of cases (7/58 unique variants). Several genotype–phenotype associations emerged: SOS1 mutations were associated with a high prevalence of cardiac defects, especially pulmonary stenosis and atrial septal defects (64% of patients, p = 0.01), whereas NF1 and SPRED1 cases had significantly fewer cardiac anomalies ( p < 0.001 and p < 0.05, respectively). Lentigines were predominantly seen in NF1 and SPRED1 patients ( p < 0.01), and all three evaluable males with MAP2K1 variants had cryptorchidism (3/3). Conversely, BRAF‐mutated patients showed lower incidence of chest deformity ( p < 0.01) but higher rates of developmental delay. NF1, SOS1, SHOC2, and BRAF together accounted for half of the non‐PTPN11 molecular diagnoses in this Russian cohort, and the observed gene‐specific clinical patterns align with previous series, although limited subgroup sizes preclude firm individual associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.
ORCID-Profile: Anna Orlova, Olga Shatokhina, Oхana Ryzkova
Zitieren
APA
Orlova, A., Shatokhina, O., Guseva, D., Demina, N., Polyakov, A., & Ryzkova, O. (2026). Genetic Spectrum of Non‐ PTPN11 Variants in Noonan Syndrome and Related RASopathies : Findings From a Russian Cohort. Clinical Genetics. https://doi.org/10.1111/cge.70211
Vancouver
Orlova A, Shatokhina O, Guseva D, Demina N, Polyakov A, Ryzkova O. Genetic Spectrum of Non‐ PTPN11 Variants in Noonan Syndrome and Related RASopathies : Findings From a Russian Cohort. Clinical Genetics. 2026. doi:10.1111/cge.70211
BibTeX
@article{Orlova2026,
author = {Orlova, Anna and Shatokhina, Olga and Guseva, Daria and Demina, Nina and Polyakov, Aleksander and Ryzkova, Oхana},
title = {Genetic Spectrum of Non‐ PTPN11 Variants in Noonan Syndrome and Related RASopathies : Findings From a Russian Cohort},
journal = {Clinical Genetics},
year = {2026},
doi = {10.1111/cge.70211}
}
EUVIMED